← Back to Screener
Anebulo Pharmaceuticals, Inc. Common Stock (ANEB)
Price$0.40
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-91.90%
Price vs S&P 500 (4W)-23.88%
VGM Score33.89
Market Capitalization$15.29M
All Metrics
Book Value / Share (Quarterly)$0.19
P/TBV (Annual)5.42x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.14
Price vs S&P 500 (YTD)-70.83%
EPS (TTM)$-0.19
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-0.19
EPS (Annual)$-0.25
ROI (Annual)-72.78%
Cash / Share (Quarterly)$0.22
ROA (Last FY)-69.86%
EBITD / Share (TTM)$-0.22
ROE (5Y Avg)-117.03%
Cash Flow / Share (Annual)$-0.15
P/B Ratio1.93x
P/B Ratio (Quarterly)5.23x
Net Income / Employee (Annual)$-4,242,400
Net Interest Coverage (TTM)-67.37x
ROA (TTM)-68.98%
EPS Incl Extra (Annual)$-0.25
Current Ratio (Annual)24.53x
Quick Ratio (Quarterly)6.12x
3-Month Avg Trading Volume0.05M
52-Week Price Return-64.29%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.33
52-Week High$3.42
EPS Excl Extra (Annual)$-0.25
26-Week Price Return-83.97%
Quick Ratio (Annual)23.99x
13-Week Price Return-6.18%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.24x
Enterprise Value$6.25M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.28
3-Month Return Std Dev159.47%
Net Income / Employee (TTM)$-3,989,400
ROE (Last FY)-72.78%
Net Interest Coverage (Annual)-31.20x
EPS Basic Excl Extra (Annual)$-0.25
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.19
ROI (TTM)-75.39%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.41
Price vs S&P 500 (52W)-88.65%
Year-to-Date Return-62.87%
5-Day Price Return-12.79%
EPS Normalized (Annual)$-0.25
ROA (5Y Avg)-111.06%
Month-to-Date Return-20.21%
Cash Flow / Share (TTM)$-0.36
EBITD / Share (Annual)$-0.27
ROI (5Y Avg)-117.03%
EPS Basic Excl Extra (TTM)$-0.19
P/TBV (Quarterly)6.89x
P/B Ratio (Annual)5.07x
Book Value / Share (Annual)$0.28
Price vs S&P 500 (13W)-14.43%
Beta-1.85x
Revenue / Share (TTM)$0.00
ROE (TTM)-75.39%
52-Week Low$0.30
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANEBAnebulo Pharmaceuticals, Inc. Common Stock | — | — | D | $0.40 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing treatments for cannabinoid toxicity and substance addiction, with operations focused in the United States. Its lead candidate, ANEB-001 (Selonabant), is designed to rapidly counteract acute cannabinoid intoxication and unintentional cannabis poisoning. The company targets an emerging therapeutic area with significant unmet medical needs.